Out of Ignorance
Contributor since: 2016
Novavax: Beware This Hypercoaster
Cardinal Health: Aristocrat Heading For A Makeover
RVL Pharmaceuticals: Chapter 2 - A Developing Quandary
Abbott's Rough Patch: What Gives?
Zomedica: Growing Veterinary Supply Company, Building Big Things On The Come
Avadel's LUMRYZ: A Good Night's Sleep For Narcolepsy Patients
Ultragenyx Pharmaceuticals: Downward Trajectory Likely To Continue
Minerva Neurosciences: Biotech On The Move
T2 Biosystems' Survival Riddle
The Alphavaxers: Dynavax And Novavax, 2 Quarters On
Omeros: Off To Never-Never Land
CEL-SCI: Enduring Challenges
Supernus: A Work In Progress
Athersys: Dead Man Walking
CTI BioPharma: One Trick Pony Ready To Perform
Inovio: After All These Years
Sorrento Therapeutics: The Enigma
Iovance: TIL Cell Therapy Set To Prove Itself
Evofem: Desperate Times, Roe v. Wade To The Rescue?
Omeros: Follow The Bouncing Ball
Gilead's Future In 3 Molecules
Intra-Cellular Therapies: A Dramatic Story
RVL Pharmaceuticals: Chapter 1 Gives A Mixed Picture
Nevro: FDA Approved Lower Back Pain Relief Without Opiates Or Surgery
Omeros: On Death's Door
Google: Turbulence Spells Opportunity
Enanta: Slow Drip
Catalyst: Upside Outlier - In Search Of A Catalyst
Horizon: For Those Who Dare
Abbott: Solid Conviction Pick
Omeros: The Weight Of The Wait, A Conundrum
RedHill: Given Up For Dead
Agenus: Not Quite Enough
Athersys - Hero Or Zero Opportunity
BioCryst: After The Fall
Chemistry X, Infinity, GRAIL: The New Illumina Is A Buy
Co-Diagnostics: Where's Eikon?
RVL Pharmaceuticals: A Makeover For An Ugly Duckling
Supernus: New Beginnings
Abbott's Bright Future In Connected Tech